甲磺酸去铁胺治疗高血压脑出血的效果分析(1)
[摘要]目的 分析甲磺酸去铁胺对高血压脑出血患者的效果。方法 选取2017年1～12月在我院住院治疗的113例高血压脑出血患者作为研究对象，根据随机数字表法将其分为两组，即对照组(53例)和研究组(60例)。对照组患者接受常规治疗，研究组患者在常规治疗基础上加用甲磺酸去铁胺治疗。分析两组患者治疗后不同时间点(治疗后7、14 d)的相对水肿体积、相对血肿体积、预后等情况。结果 治疗后7、14 d，研究组患者的相对水肿体积、相对血肿体积小于对照组，差异有统计学意义(P<0.05)；治疗后7、14 d，研究组患者的NIHSS评分低于对照组，差异有统计学意义(P<0.05)，同时研究组患者治疗后14 d的相对水肿体积、相对血肿体积均小于治疗后7 d，差异有统计学意义(P<0.05)，研究组、对照组患者治疗后14 d的NASS评分均低于治疗后7 d，差异有统计學意义(P<0.05)。结论 甲磺酸去铁胺用于治疗高血压脑出血患者的应用效果显著，不仅可以减小患者的相对血肿体积，而且能够有效缩小相对水肿体积，有助于促进患者神经功能的恢复，预后良好。
[关键词]高血压脑出血；甲磺酸去铁胺；血肿；水肿；预后
[中图分类号] R743 [文献标识码] A [文章编号] 1674-4721(2018)9(c)-0104-04
Effect analysis of Deferoxamine Mesylate on hypertensive intracerebral hemorrhage
XIONG Cheng-ying
Department of Neurosurgery， Shangrao People′s Hospital， Jiangxi Province， Shangrao 334000， China
[Abstract] Objective To analyze the effect of Deferoxamine Mesylate on hypertensive intracerebral hemorrhage. Methods A total of 113 patients with hypertensive intracerebral hemorrhage treated in our hospital from January to December 2017 were selected as study objects and they were divided into two groups according to the random digital table method， which were the control group (53 cases) and the study group (60 cases). The control group received the routine treatment. The study group was treated with Deferoxamine Mesylate on the basis of routine treatment. The relative edema volume， relative hematoma volume and prognosis at different time points (7， 14 days after treatment) were analyzed. Results At 7， 14 days after treatment， the relative edema volume and relative hematoma volume in the study group were less than those in the control group， the differences were statistically significant (P<0.05). At 7， 14 days after treatment， the NIHSS scores of the study group were lower than those of the control group (P<0.05). And the relative edema volume and relative blood of 14 days after treatment in the study group were less than those of 7 days after treatment， the differences were statistically significant (P<0.05). The NASS score of 14 days after treatment in the study group and the control group were lower than those of 7 d after treatment， and the differences were statistically significant (P<0.05). Conclusion The application of Deferoxamine Mesylate in the treatment of hypertensive intracerebral hemorrhage is significant. It can not only reduce the volume of relative hematoma， but also effectively reduce the volume of relative edema， and help to promote the recovery of nerve function and the prognosis is good., 百拇医药(熊成英)
[关键词]高血压脑出血；甲磺酸去铁胺；血肿；水肿；预后
[中图分类号] R743 [文献标识码] A [文章编号] 1674-4721(2018)9(c)-0104-04
Effect analysis of Deferoxamine Mesylate on hypertensive intracerebral hemorrhage
XIONG Cheng-ying
Department of Neurosurgery， Shangrao People′s Hospital， Jiangxi Province， Shangrao 334000， China
[Abstract] Objective To analyze the effect of Deferoxamine Mesylate on hypertensive intracerebral hemorrhage. Methods A total of 113 patients with hypertensive intracerebral hemorrhage treated in our hospital from January to December 2017 were selected as study objects and they were divided into two groups according to the random digital table method， which were the control group (53 cases) and the study group (60 cases). The control group received the routine treatment. The study group was treated with Deferoxamine Mesylate on the basis of routine treatment. The relative edema volume， relative hematoma volume and prognosis at different time points (7， 14 days after treatment) were analyzed. Results At 7， 14 days after treatment， the relative edema volume and relative hematoma volume in the study group were less than those in the control group， the differences were statistically significant (P<0.05). At 7， 14 days after treatment， the NIHSS scores of the study group were lower than those of the control group (P<0.05). And the relative edema volume and relative blood of 14 days after treatment in the study group were less than those of 7 days after treatment， the differences were statistically significant (P<0.05). The NASS score of 14 days after treatment in the study group and the control group were lower than those of 7 d after treatment， and the differences were statistically significant (P<0.05). Conclusion The application of Deferoxamine Mesylate in the treatment of hypertensive intracerebral hemorrhage is significant. It can not only reduce the volume of relative hematoma， but also effectively reduce the volume of relative edema， and help to promote the recovery of nerve function and the prognosis is good., 百拇医药(熊成英)